HPLC analysis in drug level monitoring of K027

• Autorzy: Nurulain S. M. , Kalász H. , Szegi P. , Kuca K. , Adem A. , Hasan M. Y. B. , Hashemi F. , Tekes K.
• Języki publikacji: EN

Abstrakty

EN

HPLC monitoring of pharmacokinetics was done in two body compartments of rats following intramuscular treatments with three different doses of K027, a bispyridinium mono-aldoxime type of antidotes to organoposphate intoxicated subjects. Reversed-phase HPLC separation with electrochemical detections was done to monitor the onset, the maximum level, and offset in K027 concentration. Serum level of K027 showed a fast onset, independently from the doses of K027. Drug level in brain was showing an essentially delayed kinetics.

Słowa kluczowe

EN

HPLC; K027; pharmacokinetics; blood-brain barrier; reversed-phase separation; quantitation

• Wydawca: University of Silesia in Katowice ; Akademiai Kiado
• Czasopismo: Acta Chromatographica
• Rocznik: 2013
• Tom: Vol. 25, no. 4
• Strony: 703--710
• Opis fizyczny: Bibliogr. 22 poz., rys., tab.

Twórcy

autor

Nurulain S. M.

• United Arab Emirates University Department of Pharmacology and Pharmacotherapy Al Ain United Arab Emirates

autor

Kalász H.

• Semmelweis University Department of Pharmacology and Pharmacotherapy Budapest Hungary

autor

Szegi P.

• Semmelweis University Department of Pharmacodynamics Budapest Hungary

autor

Kuca K.

• University Hospital Biomedical Research Center Hradec Kralove Czech Republic

autor

Adem A.

• United Arab Emirates University Department of Pharmacology and Pharmacotherapy Al Ain United Arab Emirates

autor

Hasan M. Y. B.

• United Arab Emirates University Department of Pharmacology and Pharmacotherapy Al Ain United Arab Emirates

autor

Hashemi F.

• Semmelweis University Department of Pharmacodynamics Budapest Hungary

autor

Tekes K.

• Semmelweis University Department of Pharmacodynamics Budapest Hungary

Bibliografia

• [1] T. Okumura, N. Takasu, S. Ishimatsu, S. Miyanoki, A. Mitsuhashi, K. Kumada, K. Tanaka, and S. Hinohara, Ann. Emerg. Med., 28, 129–135 (1996)
• [2] L.A. McCauley, G. Rischitelli, W.E. Lambert, M. Lasarev, D.L. Sticker, and P.S. Spencer, Int. J. Occup. Environ. Health, 7, 79–89 (2001)
• [3] K. Kuca, J. Bielavský, and J. Cabal, J. Bioorg. Med. Chem. Lett., 13, 3545–3547 (2003)
• [4] G.A. Petroianu, K. Arafat, K. Kuca, and J. Kassa, J. Appl. Toxicol., 26, 64–71 (2006)
• [5] K. Kuca, and J. Kassa, Vet. Hum. Toxicol., 46, 15–18 (2004)
• [6] K. Kuca, and J. Cabal, Cent. Eur. J. Public Health, 12, S59–S61 (2004)
• [7] G.A. Petroianu, S.M. Nurulain, N. Nagelkerke, M.A. Al-Sultan, K. Kuca, and J. Kassa, J. Appl. Toxicol., 26, 262–268 (2006)
• [8] G.A. Petroianu, K. Arafat, K. Kuca, and J. Kassa, J. Appl. Toxicol., 26, 64–71 (2006)
• [9] D.E. Lorke, S.M. Nurulain, M.Y. Hasan, K. Kuca, K. Musilek, and G.A. Petroianu, J. Appl. Toxicol., 28, 920–928 (2008)
• [10] P. Szegi, H. Kalász, R. Laufer, K. Kuca, and K. Tekes, Anal. Bioanal. Chem., 397, 579–586 (2010)
• [11] T. Csermely, H. Kalász, G.A. Petroianu, K. Kuca, F. Darvas, K. Ludányi, A.A. Mudhafar, and K. Tekes, Curr. Med. Chem., 15, 2401–2418 (2008)
• [12] H. Kalász, J. Fűrész, and K. Tekes, Mini-Rev. Med. Chem., 9, 596–610 (2009)
• [13] H. Kalász, É. Szökő, T. Tábi, G.A. Petroianu, D.E. Lorke, A. Omar, S. Alafifi, A. Jasem, and K. Tekes, Med. Chem., 5, 237–241 (2009)
• [14] US Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation, Center for Drug Evaluation and Research (CDER), Rockville, 2001
• [15] B. Benkő, H. Kalász, K. Ludányi, G. Petroianu, K. Kuca, F. Darvas, and K. Tekes, Anal. Bioanal. Chem., 389, 1243–1247 (2007)
• [16] K. Tekes, M.Y. Hasan, R. Sheen, K. Kuca, G. Petroianu, K. Ludányi, and H. Kalász, J. Chromatogr. A, 1122, 84–87 (2006)
• [17] M. Gyenge, H. Kalász, G.A. Petroianu, R. Laufer, K. Kuca, and K. Tekes, J. Chromatogr. A, 1161, 146–151 (2007)
• [18] H. Kalász, M.Y. Hasan, R. Sheen, K. Kuca, G. Petroianu, K. Ludányi, A. Gergely, and K. Tekes, Anal. Bioanal. Chem., 385, 1062–1067 (2006)
• [19] K. Musilek, D. Jun, J. Cabal, J. Kassa, F. Gunn-Moore, and K. Kuca, J. Med. Chem., 50, 5514–5518 (2007)
• [20] K. Sakurada, K. Matsubara, K. Shimizu, H. Shiono, Y. Seto, K. Tsuge, M. Yoshino, I. Sakai, H. Mukoyama, and T. Takatori, Neurochem. Res., 28, 1401–1407 (2003)
• [21] S. Okuno, K. Sakurada, H. Ohta, H. Ikegaya, Y. Kazui, T. Akutsu, T. Takatori, and K. Iwadate, Toxicol. Appl. Pharmacol., 227, 8–15 (2008)
• [22] D.E. Lorke, H. Kalász, G.A. Petroianu, and K. Tekes, Curr. Med. Chem., 15, 743–753 (2008)